IL6 and Miyoshi myopathy: Finally, to confirm that the increased proliferation was due to the production of IL-6 in BMSCs, we repeated the experiments that were applied for LP-1 and H929 before in IL-6 dependent MM cell line ANBL-6, the result (Figure 7F) showed that rIL-32α-treated BCCM had nearly the same effect compared to normal medium with rIL-6 (20ng/mL) (e.g., ANBL-6, rIL-32α 40ng/mL 72h, 4.60±0.17 vs 5.65±0.18), IL-6 neutralization antibodies (20ng/mL) significantly inhibited the proliferation of ANBL-6 cells cultured in BCCM (e.g., ANBL-6, rIL-32α 40ng/mL+IL-6 neutral 72h, 2.64±0.51 vs 4.60±0.17, p<0.05).